DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
DA Davidson analyst Linda Bolton Weiser maintains a Neutral rating on Medifast (NYSE:MED) and lowers the price target from $40 to $25.
April 30, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DA Davidson analyst maintains a Neutral rating on Medifast and reduces the price target from $40 to $25.
The reduction in price target by DA Davidson suggests a bearish outlook on Medifast's stock value in the short term, likely due to anticipated underperformance or market conditions affecting the company's future earnings potential. This adjustment in price target can influence investor sentiment and potentially lead to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100